Entresto (sacubitril/valsartan) - Novartis, ROVI Pharmaceuticals Laboratories
A prospective randomized controlled clinical study of the effect of sacubitril/valsartan on serum uric acid level in patients with hypertension and asymptomatic hyperuricemia (ChiCTR) - Oct 16, 2026 - P4 | N=150 | Completed | Sponsor: The Second Affiliated Hospital of Nanchang University; The Second Affiliated Hospital of Nanchang University | Not yet recruiting ➔ Completed | Phase classification: PN/A ➔ P4 
Phase classification • Trial completion • Cardiovascular • Hypertension
https://www.chictr.org.cn/showproj.html?proj=127701
 
Oct 16, 2026
 
Prev Next